Structure-based drug design: The discovery of novel nonpeptide orally active inhibitors of human renin

Chemistry and Biology

Volumn 7, Issue 7, 2000, Pages 493-504

  Rahuel, J ^a   Rasetti, V ^a   Maibaum, J ^a   Rueger H ^a   Goschke R ^a   Cohen, N C ^a   Stutz, S ^a   Cumin, F ^a   Fuhrer, W ^a   Wood, J ^a   Grutter M G ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Drug design; Hypertension; Inhibitor binding; Renin; X ray crystallography

Indexed keywords

ANIMALIA; MARMOSETS; PRIMATES;

EID: 0033941893     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00134-4     Document Type: Article

References (52)

1. Reid I.A., Morris R.J., Ganong W.F. The renin-angiotensin system. Ann. Rev. Physiol. 40:1978;377-410.
2. Skeggs L.T., Doven F.E., Levins M., Lentz K., Kahn J.R. The biochemistry of the renin-angiotensin system. Johnson J.A., Anderson R.R. The Renin-Angiotensin System. 1980;1-27 Plenum Press, New-York.
3. Hofbauer K.G., Wood J.M. Renin inhibitors as possible antihypertensive agents. Klin. Wochenschr. 66:1985;906-913.
4. Sweet C.S., Blaine E.H. Angiotensin converting enzyme inhibitors. Zanchetti A., Tarazzi R.C. Handbook of Hypertension. 1984;343-363 Elsevier, Amsterdam, The Netherlands.
5. Johnston C.I. Angiotensin converting enzyme inhibitors. Zanchetti A., Tarazzi R.C. Handbook of Hypertension. 1984;272-311 Elsevier, Amsterdam, The Netherlands.
6. Zanchetti A., Tarazzi R.C. Symposium on angiotensin-converting enzyme, a developing therapeutic concept. Am. J. Cardiol. 49:1982;1381-1579.
7. Hofbauer K.G., Hulthén L.U., Bülher F.R. Antagonists and inhibitors of the renin-angiotensin system for the treatment of hypertension. Genest J., Kuchel O., Hamet P., Cantin M. Hypertension, Physiopathology and Treatment. 1983;1225-1238 McGraw-Hill, New-York.
8. Brunner N.R., Nussberger J., Waeber B. Effects of angiotensin converting enzyme inhibition: a clinical point of view. J. Cardiovasc. Pharmacol. 7(Suppl 4):1995;73-81.
9. Waeber B., Nussberger J., Brunner H.R. Angiotensin-converting enzyme inhibitors in hypertension. Laragh J.H., Brenner B.M. Hypertension: Pathophysiology, Diagnosis and Management, 2nd edition. 1995;2861-2876 Raven Press, New York.
10. Ondetti M.A., Cushman D.W. Enzymes of the renin-angiotensin system and their inhibitors. Ann. Rev. Biochem. 51:1982;283-308.
11. Antonaccio M.J. Inhibitors of the renin-angiotensin system as new antihypertensive agents. Clin. Exp. Hypertens. A. 4:1982;27-46.
12. Hofbauer K.G., Wood J.M. The renin-angiotensin system, inhibitors and antagonists. Zanchetti A., Tarazzi R.C. Handbook of Hypertension, volume 8. 1986;466-488 Elsevier, Amsterdam, The Netherlands.
13. Nelson E.B., Harm S.C., Goldberg M., Shahinfar S., Goldbeg A., Sweet C.S. Clinical profile if the first angiotensin II (AT-1 specific) receptor antagonists. Laragh J.H., Brenner B.M. Hypertension: Pathophysiology, Diagnosis and Management, 2nd edition. 1995;2895-2916 Raven Press, New York.
14. Chen K.C.S., Tang J. Amino acid sequence around the epoxide-reactive residues in pepsin. J. Biol. Chem. 247:1972;2566-2574.
15. Hartsuck J.A., Tang J. The carboxylate ion in the active centre of pepsin. J. Biol. Chem. 247:1972;2575-2580.
16. Grütter M.G., Rahuel J. Human renin: biochemistry, crystal structure, and opportunities for development of specific inhibitors. Laragh J.H., Brenner B.M. Hypertension: Pathophysiology, Diagnosis and Management, 2nd edition. 1995;1607-1619 Raven Press, New York.
17. Sielecki A.R., James M.N.G.et al. Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 Å resolution. Science. 243:1989;1346-1351.
18. Rahuel J., Priestle J.P., Grütter M.G. The crystal structures of recombinant glycosylated human renin alone and in complex with a transition-state analog inhibitor. J. Struct. Biol. 107:1991;227-236.
19. Dhanaraj V., Hoover D.J.et al. X-ray analyses of peptide-inhibitor complexes define the structural basis of specificity for human and mouse renins. Nature. 357:1992;466-472.
20. Tong L., Jung G.et al. High resolution crystal structures of recombinant human renin in complex with polyhydroxymonoamide inhibitors. J. Mol. Biol. 250:1995;211-222.
21. Tong L., Pav S., Lamarre D., Simoneau B., Lavallée P., Jung G. Crystallographic studies on the binding modes of P2-P3 butanediamide renin inhibitors. J. Biol. Chem. 270:1995;29520-29524.
22. Wood J., Cumin F., Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Heagerty A.M. Pharmac. Ther. 1994;325-344 Elsevier Science Ltd, UK.
23. Szelke M., Lever A.F.et al. Potent new inhibitors of human renin. Nature. 299:1982;555-557.
24. Boger J., Bopari A.S.et al. Novel renin inhibitors containing the amino acid statin. Nature. 303:1983;81-84.
25. Ripka A.S., Rich D.H. Peptidomimetic design. Curr. Opin. Chem. Biol. 4:1998;439-452.
26. Bühlmayer P., Wood J.M.et al. Synthesis and biological activity of some transition-state inhibitors of human renin. J. Med. Chem. 31:1988;1839-1846.
27. Schechter I., Berger A. On the size of the active site of proteases. I. Papain. Biochem. Biophys. Res. Commun. 27:1967;157-162.
28. Wood J.M., Kay J.et al. CGP 38560: Orally active, low molecular weight renin inhibitor with high potency and specificity. J. Cardiovasc. Pharmacol. 14:1989;221-226.
29. Maibaum J., Wood J.M.et al. Design and synthesis of novel potent, nonpeptide and orally active renin inhibitors. Gujral P.D. Medicinal Chemistry: Today and Tomorrow. 1996;155-162 Blackwell Science Ltd, Oxford.
30. Rasetti V., Wood J.M.et al. Bioactive hydroxyethylene dipeptide isosteres with hydrophobic (P3-P1)-moieties. A novel strategy towards small nonpeptide renin inhibitors. Bioorg. Med. Chem. Lett. 6:1996;1589-1594.
31. Sibanda B.L., Chirgwin J.M.et al. Computer graphics modelling of human renin. Specificity, catalytic activity and intron-exon junctions. FEBS Lett. 174:1984;102-111.
32. Cohen N.C. Molecular mimics and drug design. van der Goot H., Domány L., Pallos L., Timmerman H. Trends in Medicinal Chemistry 88. 1989;13-28 Elsevier, Amsterdam.
33. Plummer M., Rapundalo S.T.et al. Design and synthesis of renin inhibitors. Incorporation of transition-state isostere sidechains that span from the S1 to the S3 binding pockets and examination of P3-modified renin inhibitors. J. Med. Chem. 38:1995;2893-2905.
34. Lefker B.A., Sneddon S.F.et al. Rational design, synthesis and X-ray structure of renin inhibitors with extended P1 sidechains. Bioorg. Med. Chem. Lett. 5:1995;2623-2626.
35. Göschke R., Cohen N.C., Wood J.M., Maibaum J. Design and synthesis of novel 2,7-dialkyl substituted 5(S)-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin. Bioorg. Med. Chem. Lett. 7:1997;2735-2740.
36. Göschke, R., et al., & Maibaum, J. (1998). Novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin. XVth EFMC Int. Symp. Med. Chem, Edinburgh (UK), 6-10 Sept 1998; Abstract Book, p. 229.
37. sp-P3)-moiety with high oral in vivo potency. XVth EFMC Int. Symp. Med. Chem, Edinburgh (UK), 6-10 Sept 1998; Abstract Book, p. 231.
38. Maibaum, J., et al., & Wood, J.M. (1998). Structural modification of the P2′ position of 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: discovery of a potent non-peptide human renin inhibitor active after once daily dosing in marmosets. XVth EFMC Int. Symp. Med. Chem, Edinburgh (UK), 6-10 Sept 1998; Abstract Book, p. 230.
39. Oefner C., Wostl W.et al. Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases? Chem. Biol. 6:1999;127-131.
40. Asselbergs F.A.M., Rahuel J., Cumin F., Leist C. Scaled-up production of recombinant human renin in CHO cells for enzymatic and X-ray structure analysis. J. Biotechnol. 32:1994;191-202.
41. Lim L.W., Stegeman R.A., Leimgruber N.K., Gierse J.K., Abdel-Meguid S.S. Preliminary crystallographic study of glycosylated recombinant human renin. J. Mol. Biol. 210:1989;239-240.
42. Messerschmidt A., Pflugrath J.W. Crystal orientation and X-ray pattern prediction for area-detector diffractometer systems in macromolecular crystallography. J. Appl. Crystallogr. 20:1987;306-315.
43. The CCP4 suite, programs for protein crystallography. Acta Crystallogr. D. 50:1994;760-763.
44. Kabsch W. Evaluation of a single crystal diffraction form a position-sensitive detector. J. Appl. Crystallogr. 21:1988;916-924.
45. Tronrud D.E., Ten Eyck L.F., Matthews B.W. An efficient general-purpose least-square refinement program for macromolecular structures. Acta Crystallogr. A. 43:1987;489-501.
46. Brünger A.T. X-PLOR Version 3.1 A system for X-ray Crystallography and NMR. 1992;Yale University Press, New Haven and London, UK.
47. Jones A.T., Zou J.-Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
48. Schnell C.R., Wood J.M. Measurement of blood pressure and heart rate by telemetry in conscious, unrestrained marmosets. Am. J. Physiol. 264:1993;H1509-H1516.
49. Kraulis P. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Cryst. 24:1991;946-950.
50. Bacon D.J., Anderson W.F. A fast algorithm for rendering space-filling molecule pictures. J. Mol. Graph. 6:1998;219-220.
51. Merritt E.A., Murphy M.E.P. Raster3D version2.0 - a program for photorealistic molecular graphics. Acta Crystallogr. D. 50:1994;869-873.
52. Nichols A., Sharp K.A., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 11:1991;281-296.